Payment overview · 2025
General Payments
$253.29
14 reported records · 10 companies
Healthcare provider profile · identity verified
Sheldon Jon Harigel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAWRENCEBURG, TN · NPI 1407090731
Verified facts
What the public records show
CMS Open Payments records show Sheldon Jon Harigel, M.D. received $253.29 in general payments during 2025 across 14 reported records.
Exact Sciences Corporation accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.03 | 21.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.32 | 13.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.09 | 11.9% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.81 | 10.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.22 | 9.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.16 | 8.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.90 | 7.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.56 | 6.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.45 | 5.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $13.75 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.29 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.03 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
103 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 450 | 141 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 370 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 365 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 92 |
| Gabapentin | Gabapentin | 278 | 81 |
| Metformin Hcl | Metformin Hcl | 268 | 82 |
| Furosemide | Furosemide | 258 | 86 |
| Losartan Potassium | Losartan Potassium | 231 | 66 |
| Potassium Chloride | Potassium Chloride | 208 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 65 |
| Omeprazole | Omeprazole | 182 | 60 |
| Lisinopril | Lisinopril | 174 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 52 |
| Meloxicam | Meloxicam | 153 | 52 |
| Tramadol Hcl | Tramadol Hcl | 146 | 42 |
| Ozempic | Semaglutide | 145 | 31 |
| Methylprednisolone | Methylprednisolone | 142 | 122 |
| Eliquis | Apixaban | 137 | 27 |
| Pregabalin | Pregabalin | 137 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 135 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 36 |
| Alprazolam | Alprazolam | 115 | 19 |
| Lorazepam | Lorazepam | 112 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 35 |
| Mounjaro | Tirzepatide | 103 | 13 |
| Simvastatin | Simvastatin | 103 | 30 |
| Carvedilol | Carvedilol | 101 | 35 |
| Trazodone Hcl | Trazodone Hcl | 97 | 40 |
| Allopurinol | Allopurinol | 93 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 31 |
| Tresiba Flextouch U-200 | Insulin Degludec | 91 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 26 |
| Montelukast Sodium | Montelukast Sodium | 83 | 30 |
| Clonazepam | Clonazepam | 79 | 15 |
| Famotidine | Famotidine | 78 | 27 |
| Celecoxib | Celecoxib | 74 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 24 |
| Glipizide | Glipizide | 62 | 19 |
| Sucralfate | Sucralfate | 61 | 19 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Myrbetriq | Mirabegron | 57 | 13 |
| Prednisone | Prednisone | 57 | 34 |
| Clonidine Hcl | Clonidine Hcl | 54 | 20 |
| Ibuprofen | Ibuprofen | 49 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 16 |
| Azithromycin | Azithromycin | 48 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 35 |
| Levofloxacin | Levofloxacin | 45 | 40 |
| Temazepam | Temazepam | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 25 |
| Buspirone Hcl | Buspirone Hcl | 40 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | suppressed |
| Cefdinir | Cefdinir | 35 | 28 |
| Donepezil Hcl | Donepezil Hcl | 35 | 14 |
| Atenolol | Atenolol | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 14 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 13 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Linzess | Linaclotide | 31 | 14 |
| Estradiol | Estradiol | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Finasteride | Finasteride | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | 11 |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 18 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 14 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | 14 |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.29 · 14 records | Exact Sciences Corporation | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Extended Holter, FREESTYLE LIBRE 3, GEMTESA, GIVLAARI, INCEPTIV, MOUNJARO, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error